D8 i) Use of a reducing agent (e.g. $NaCNBH_3$, BH_3, hydrogen plus catalyst, $LiHBEt_3$, di-isobutyl-aluminiumhydride, lithium aluminium hydride, sodium borohydride) in the presence of a suitable solvent e.g. ethanol and acetic acid.

Please further amend the fifth paragraph on page 33, line 28 to page 34, line 2, as follows:

(Twice Amended) Compounds of Formula I in which G represents $-CH_2-NR^{16}-T-$, $-CH_2-O-T-$ or $-CH_2-S-T-$ may be prepared as outlined in Scheme 5 in which LG represents a leaving group (e.g. mesyloxy, tosyloxy, halogen) and X represents O, S or NR^{16}. Suitable coupling conditions are as outlined above in relation to Scheme 2. Optionally the positions of LG and XH in compounds 1 and 2 in Scheme 5 can be reversed to give the same end product.

D9

IN THE CLAIMS:

Please further amend claims 7 and 8 as follows:

7. **(Three Times Amended)** A compound of the formula B:

D10



B

wherein:

X is O or H_2;

e is 0;

t is 1 to 4;

$R^{2'}$, $R^{3'}$, $R^{4'}$, and $R^{5'}$ are independently selected from: H; C_{1-8}alkyl, alkenyl, alkynyl, aryl, heterocycle, -CO-$NR^{6'}R^{7'}$ or -CO-$OR^{6'}$, unsubstituted or substituted with one or more of:

1) aryl or heterocycle, unsubstituted or substituted with:
   a. C_{1-4}alkyl,
   b. $(CH_2)_tOR^{6'}$,
   c. $(CH_2)_tNR^{6'}R^{7'}$,
   d. halogen,
2) C_{3-6}cycloalkyl,
3) $OR^{6'}$,
4) $SR^{6'}$, $S(O)R^{6'}$, $SO_2R^{6'}$,
5) -$NR^{6'}R^{7'}$,
6) -$NR^{6'}$-CO-$R^{7'}$,
7) -$NR^{6'}$-CO-$NR^{7'}R^{8'}$,
8) -O-CO-$NR^{6'}R^{7'}$,
9) -O-CO-$OR^{6'}$,
10) -O-$NR^{6'}R^{7'}$,
11) -$SO_2NR^{6'}R^{7'}$,
12) -$NR^{6'}$-SO_2-$R^{7'}$,
13) -CO-$R^{6'}$, or
14) -CO-$OR^{6'}$;

and any two of $R^{2'}$, $R^{3'}$, $R^{4'}$, and $R^{5'}$ are optionally attached to the same carbon atom;

Y is aryl, heterocycle, unsubstituted or substituted with one or more of:

1) C_{1-4}alkyl, unsubstituted or substituted with:
   a. C_{1-4}alkoxy,
   b. $NR^{6'}R^{7'}$,
   c. C_{3-6}cycloalkyl,
   d. aryl or heterocycle,
   e. HO,

2) aryl or heterocycle,

3) halogen,

4) $OR^{6'}$,

5) $NR^{6'}R^{7'}$,

6) CN

7) NO_2, or

8) CF_3;

$R^{6'}$, $R^{7'}$ and $R^{8'}$ are independently selected from: H; C_{1-4}alkyl, C_{3-6}cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with:

a) C_{1-4}alkoxy,

b) aryl or heterocycle,

c) halogen,

d) HO,

e) $-CO-R^{9'}$,

f) $-SO_2R^{9'}$, wherein

$R^{6'}$ and $R^{7'}$ may be joined in a ring, and

$R^{7'}$ and $R^{8'}$ may be joined in a ring;

$R^{9'}$ is C_{1-4}alkyl or aralkyl;

a pharmaceutically acceptable salt thereof.

8. **(Three Times Amended)** The compound (2S)-2-(2-methoxy-ethyl)-1-((cis)-3-sulfanyl-pyrrolidin-2-ylmethyl)-4-naphthoyl-piperazine or a pharmaceutically acceptable salt thereof.